Open Access iconOpen Access

REVIEW

Circulating Tumor DNA in Cervical Cancer: Clinical Utility and Medico-Legal Perspectives

Abdulrahman K. Sinno1, Aisha Mustapha1, Navya Nair1, Simona Zaami2, Lina De Paola2, Valentina Billone3, Eleonora Conti3, Giuseppe Gullo3,*, Pasquale Patrizio4

1 Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA
2 Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Rome, 00161, Italy
3 Department of Obstetrics and Gynecology, AOOR Villa Sofia–Cervello, University of Palermo, Palermo, 90127, Italy
4 Division of Reproductive Endocrinology & Infertility, University of Miami Miller School of Medicine, Miami, FL 33136, USA

* Corresponding Author: Giuseppe Gullo. Email: email

Oncology Research 2026, 34(1), . https://doi.org/10.32604/or.2025.072176

Abstract

Cervical cancer related to human papillomavirus (HPV) is a leading cause of cancer-related mortality among women worldwide. Cancer cells release fragments of their DNA, known as circulating tumor DNA (ctDNA), which can be detected in bodily fluids. A PubMed search using the terms “ctHPV” or “circulating tumor DNA” and “cervical cancer”, limited to the past ten years, identified 104 articles, complemented by hand-searching for literature addressing medico-legal implications. Studies were evaluated for relevance and methodological quality. Detection and characterization of circulating tumor HPV DNA (ctHPV DNA) have emerged as promising tools for assessing prognosis and disease recurrence in cervical cancer. Detection techniques include polymerase chain reaction (PCR), digital droplet PCR (ddPCR), and next-generation sequencing (NGS). This review summarizes current knowledge on ctHPV DNA in cervical cancer and explores its clinical and medico-legal implications, including management of discordant results, diagnostic errors, liability, and data protection compliance.

Keywords

Circulating tumor DNA; circulating tumor human papillomavirus; cervical cancer; medico-legal implications

Cite This Article

APA Style
Sinno, A.K., Mustapha, A., Nair, N., Zaami, S., Paola, L.D. et al. (2026). Circulating Tumor DNA in Cervical Cancer: Clinical Utility and Medico-Legal Perspectives. Oncology Research, 34(1). https://doi.org/10.32604/or.2025.072176
Vancouver Style
Sinno AK, Mustapha A, Nair N, Zaami S, Paola LD, Billone V, et al. Circulating Tumor DNA in Cervical Cancer: Clinical Utility and Medico-Legal Perspectives. Oncol Res. 2026;34(1). https://doi.org/10.32604/or.2025.072176
IEEE Style
A. K. Sinno et al., “Circulating Tumor DNA in Cervical Cancer: Clinical Utility and Medico-Legal Perspectives,” Oncol. Res., vol. 34, no. 1, 2026. https://doi.org/10.32604/or.2025.072176



cc Copyright © 2026 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 551

    View

  • 345

    Download

  • 0

    Like

Share Link